Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology - 1 Jan 2009

Roses Allen D

Abstract excerpt

Pharmacogenetics (PGX) is the study of drug response as a function of an individual's DNA. PGX is often viewed as an extension of disease association genetics, and although this information may be related, it is not the study of drug response. Although medicines are used to treat diseases, the value of strategies that identify and incorporate DNA biomarkers associated with clinical efficacy, or DNA biomarkers for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Pharmacological
Share to Cost-Benefit Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dideoxynucleosides

Share to Drug Hypersensitivity

Share to Drug-Related Side Effects and Adverse Reactions

Share to Rosiglitazone

Share to Sample Size

Share to Thiazolidinediones

Source

Identifiers

PMID: 18923406
DOI: 10.1038/npp.2008.153

Genes

APOE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety.PMID 18923406Read ↗

Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease).Semantic proximity Read ↗

Pharmacogenomics in early-phase clinical development.Semantic proximity Read ↗

The genetics of drug efficacy: opportunities and challenges.Semantic proximity Read ↗

A genomic-led strategy to anticipate drug safety effects.Semantic proximity Read ↗

Opportunities in pharmacogenomics for the treatment of Alzheimer’s diseaseSemantic proximity Read ↗

Prospective–Retrospective Biomarker Analysis for Regulatory Consideration: white Paper from the Industry Pharmacogenomics Working GroupSemantic proximity Read ↗

Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval.Semantic proximity Read ↗

Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions.Semantic proximity Read ↗

Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approvalSemantic proximity Read ↗

Genotype-based risk and pharmacogenetic sampling in clinical trials.Semantic proximity Read ↗

Successful translation of pharmacogenetics into the clinic: the abacavir example.Semantic proximity Read ↗

Clinical trials in the genomic era: effects of protective genotypes on sample size and duration of trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.